Meghan Oliver's practice focuses on complex litigation and class actions, including work on securities fraud cases, general commercial litigation, and consumer fraud litigation.Meghan is actively involved in various class actions, including several against health insurers for drug and equipment overcharges, and one alleging that the Administrative Office of the U.S. Courts charges more for PACER services than is authorized by statute (Nat'l Veterans Legal Services Program v. United States, Case No. 16-745-ESH). She also represents large public pension funds, unions, and institutional investors in securities fraud class actions, including In re Twitter, Inc. Securities Litigation, No. 3:16-cv-05315-JST-SK and In re Qualcomm Inc. Securities Litigation, No. 17-CV-00121-JAH-WVG. Additionally, Meghan helps to lead litigation filed for a class consisting of more than a million tax return preparers alleging the IRS charged unauthorized user fees for the issuance and renewal of preparer tax identification numbers, (Steele v. United States, Case No. 1:14-cv-1523-RCL).She has also worked on several antitrust matters in the past, including In re North Sea Brent Crude Oil Futures Litigation, In re Libor-Based Financial Instruments Antitrust Litigation, and generic drug cases involving "reverse payment" agreements.Prior to joining Motley Rice, Meghan worked as a business litigation and antitrust associate in Washington, D.C. There, she assisted in the trial of a multidistrict litigation antitrust case and assisted in multiple corporate internal investigations. She is a member of Phi Beta Kappa.Awards and AccoladesLawdragon 2019-2023 Lawdragon 500 Plaintiff Financial LawyersNational Law Journal 2022 Litigation Trailblazer Related Blog Posts February 26, 2020 Decade in Review: Plaintiffs' Litigation Highlights Causes, Not Just Cases by: Joseph F. Rice September 2, 2016 The 400 Percent Question: Why so few generic alternatives to Mylan's EpiPen? Causes, Not Just Cases by: Michael M. Buchman December 16, 2014 Pleading antitrust injury in the absence of FDA approval of a drug Causes, Not Just Cases by: Michael M. Buchman Related News October 13, 2022 Represented by Motley Rice and co-counsel, PACER users reach $125 million preliminary settlement to refund fees by: Motley Rice April 13, 2022 Benchmark Litigation names Motley Rice Plaintiff Firm of the Year by: Motley Rice January 20, 2022 Law360 Names Motley Rice a 2021 Securities Practice Group of the Year by: Motley Rice